Cargando…

Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease

BACKGROUND: Dual antiplatelet therapy (DAPT) is currently the standard treatment for the prevention of ischemic events after stent implantation. However, the optimal DAPT duration remains elusive for patients with chronic kidney disease (CKD). Therefore, we aimed to compare the effectiveness and saf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Chih-Chin, Wu, Mai-Szu, Chuang, Ming-Tsang, Lin, Yi-Cheng, Huang, Chun-Yao, Chang, Wei-Chiao, Chen, Chih-Wei, Chang, Tzu-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336855/ https://www.ncbi.nlm.nih.gov/pubmed/34347826 http://dx.doi.org/10.1371/journal.pone.0255645

Ejemplares similares

Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function
por: Kao, Chih-Chin, et al.
Publicado: (2021)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Association of UBE3C Variants with Reduced Kidney Function in Patients with Diabetic Kidney Disease
por: Chen, Ying-Chun, et al.
Publicado: (2020)

Coronary Stent Infection Presented as Recurrent Stent Thrombosis
por: Lai, Chih-Hung, et al.
Publicado: (2017)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets
por: Hsia, Chih-Hsuan, et al.
Publicado: (2018)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
por: Jhang, Kai-Ming, et al.
Publicado: (2015)

Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients
por: Park, Seokwoo, et al.
Publicado: (2020)

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
por: Geng, Xue, et al.
Publicado: (2020)

Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?
por: Chang, Mineok, et al.
Publicado: (2014)

Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Long‐Term Outcomes
por: Kinlay, Scott, et al.
Publicado: (2021)

Adherence to dual antiplatelet therapy after coronary stenting: A study conducted at two Vietnamese hospitals
por: Tien Hoang, Anh, et al.
Publicado: (2021)

Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review
por: Carciotto, Gabriele, et al.
Publicado: (2023)

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
por: Tung, Ying-Chang, et al.
Publicado: (2020)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients
por: Wong, Henry Sung-Ching, et al.
Publicado: (2017)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
por: Sudhir, Krishnankutty, et al.
Publicado: (2013)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

A case report of atraumatic splenic rupture after coronary stenting and dual antiplatelet therapy: Causality or relationship?
por: Boccanelli, Paolo, et al.
Publicado: (2021)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Effects of Periodontal Treatment in Patients with Periodontitis and Kidney Failure: A Pilot Study
por: Chung, Wen-Chen, et al.
Publicado: (2022)

Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy
por: Egholm, Gro, et al.
Publicado: (2016)

Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent
por: De Vecchis, Renato, et al.
Publicado: (2016)

Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis
por: Luo, Lin, et al.
Publicado: (2022)

Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012
por: Lin, Yen-Chung, et al.
Publicado: (2015)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

The role of genetic polymorphisms in STIM1 and ORAI1 for erythropoietin resistance in patients with renal failure
por: Kao, Chih-Chin, et al.
Publicado: (2021)

Dual antiplatelet treatment after coronary artery bypass surgery
por: Lopez Menendez, Jose, et al.
Publicado: (2015)

Dual antiplatelet therapy for secondary prevention of coronary artery disease
por: Degrauwe, Sophie, et al.
Publicado: (2017)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
por: Wada, Tadashi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dv69jch363bhljosg47kh7ogce